MA29262B1 - Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 - Google Patents

Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2

Info

Publication number
MA29262B1
MA29262B1 MA30158A MA30158A MA29262B1 MA 29262 B1 MA29262 B1 MA 29262B1 MA 30158 A MA30158 A MA 30158A MA 30158 A MA30158 A MA 30158A MA 29262 B1 MA29262 B1 MA 29262B1
Authority
MA
Morocco
Prior art keywords
diabetes
prevention
preparation
treatment
rimonabant
Prior art date
Application number
MA30158A
Other languages
English (en)
French (fr)
Inventor
Corinne Hanotin
Pierre Rosenzweig
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0501861A external-priority patent/FR2882261B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA29262B1 publication Critical patent/MA29262B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA30158A 2005-02-21 2007-08-23 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 MA29262B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (fr) 2005-02-21 2005-02-21 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0504942A FR2882264A1 (fr) 2005-02-21 2005-05-12 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0505228A FR2882265B1 (fr) 2005-02-21 2005-05-23 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.

Publications (1)

Publication Number Publication Date
MA29262B1 true MA29262B1 (fr) 2008-02-01

Family

ID=36809538

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30158A MA29262B1 (fr) 2005-02-21 2007-08-23 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2

Country Status (10)

Country Link
JP (1) JP2008530189A (es)
BR (1) BRPI0608183A2 (es)
CR (1) CR9293A (es)
EA (1) EA011618B1 (es)
FR (2) FR2882264A1 (es)
IL (1) IL185401A0 (es)
MA (1) MA29262B1 (es)
MX (1) MX2007009996A (es)
TN (1) TNSN07297A1 (es)
TW (1) TW200640457A (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Also Published As

Publication number Publication date
CR9293A (es) 2007-10-01
TNSN07297A1 (en) 2008-12-31
TW200640457A (en) 2006-12-01
FR2882264A1 (fr) 2006-08-25
EA200701781A1 (ru) 2007-12-28
JP2008530189A (ja) 2008-08-07
BRPI0608183A2 (pt) 2009-11-17
MX2007009996A (es) 2007-10-10
EA011618B1 (ru) 2009-04-28
FR2882265A1 (fr) 2006-08-25
IL185401A0 (en) 2008-08-07
FR2882265B1 (fr) 2009-02-13

Similar Documents

Publication Publication Date Title
HK1121074A1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
HUP0301729A2 (hu) Gyógyszer szívelégtelenség megelżzésére és kezelésére
BRPI0511527A (pt) compostos e composições como moduladores de ppar
EA202091999A3 (ru) Применение ингибиторов dpp iv
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
Schmidinger et al. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
WO2008149802A1 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
DK1680128T3 (da) Myo-inositolhexaphosphat til topisk anvendelse
EP1870099A4 (en) PROTECTIVE AGENT FOR RETINAL NEURAL CELL COMPRISING AN INDAZOLE DERIVATIVE AS ACTIVE INGREDIENT
WO2006108681A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
NO20076405L (no) Anvendelse av 24-nor-UDCA
MA29145B1 (fr) Préparations pharmaceutiques pour le traitement de la cellulite
DK1482919T3 (da) Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes
FR2919187B1 (fr) Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
TW200503676A (en) Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
MA29262B1 (fr) Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR2907682B1 (fr) Composition cosmetique et/ou pharmaceutique comprenant comme principe actif au moins un peptide et utilisation de ce peptide.
FR2885128B1 (fr) Composition cosmetique a visee depigmentante ou eclaircissante comprenant au moins une oxazoline, a titre de principe actif depigmentant ou eclaircissant